226 related articles for article (PubMed ID: 11509325)
21. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
22. Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis.
Harrison JH; Lazo JS
J Pharmacol Exp Ther; 1988 Dec; 247(3):1052-8. PubMed ID: 2462625
[TBL] [Abstract][Full Text] [Related]
23. Effects of delayed treatment with transforming growth factor-beta soluble receptor in a three-dose bleomycin model of lung fibrosis in hamsters.
Wang Q; Hyde DM; Gotwals PJ; Giri SN
Exp Lung Res; 2002 Sep; 28(6):405-17. PubMed ID: 12217209
[TBL] [Abstract][Full Text] [Related]
24. Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.
Segel MJ; Aqeilan R; Zilka K; Lorberboum-Galski H; Wallach-Dayan SB; Conner MW; Christensen TG; Breuer R
Int J Exp Pathol; 2005 Oct; 86(5):279-88. PubMed ID: 16191100
[TBL] [Abstract][Full Text] [Related]
25. Preventive and early therapeutic effects of β-glucan on the bleomycin-induced lung fibrosis in rats.
Iraz M; Bilgic S; Samdanci E; Ozerol E; Tanbek K; Iraz M
Eur Rev Med Pharmacol Sci; 2015 Apr; 19(8):1505-16. PubMed ID: 25967727
[TBL] [Abstract][Full Text] [Related]
26. Protective effects of a bacterially expressed NIF-KGF fusion protein against bleomycin-induced acute lung injury in mice.
Li X; Li S; Zhang M; Li X; Zhang X; Zhang W; Li C
Acta Biochim Biophys Sin (Shanghai); 2010 Aug; 42(8):548-57. PubMed ID: 20705596
[TBL] [Abstract][Full Text] [Related]
27. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice.
Izumo T; Kondo M; Nagai A
Life Sci; 2007 Apr; 80(20):1882-6. PubMed ID: 17397875
[TBL] [Abstract][Full Text] [Related]
28. (5R)-5-hydroxytriptolide (LLDT-8) protects against bleomycin-induced lung fibrosis in mice.
Ren YX; Zhou R; Tang W; Wang WH; Li YC; Yang YF; Zuo JP
Acta Pharmacol Sin; 2007 Apr; 28(4):518-25. PubMed ID: 17376291
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of bleomycin-induced lung fibrosis by oral sulfhydryl containing antioxidants in rats: erdosteine and N-acetylcysteine.
Yildirim Z; Kotuk M; Iraz M; Kuku I; Ulu R; Armutcu F; Ozen S
Pulm Pharmacol Ther; 2005; 18(5):367-73. PubMed ID: 15939316
[TBL] [Abstract][Full Text] [Related]
30. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
[TBL] [Abstract][Full Text] [Related]
31. Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis.
Lin C; Duitman J; Daalhuisen J; Ten Brink M; von der Thüsen J; van der Poll T; Borensztajn K; Spek CA
Thorax; 2014 Feb; 69(2):152-60. PubMed ID: 24029744
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of elastin and alpha 1(I) collagen mRNA in mice with bleomycin-induced pulmonary fibrosis.
Lucey EC; Ngo HQ; Agarwal A; Smith BD; Snider GL; Goldstein RH
Lab Invest; 1996 Jan; 74(1):12-20. PubMed ID: 8569173
[TBL] [Abstract][Full Text] [Related]
33. Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice.
Ou XM; Feng YL; Wen FQ; Huang XY; Xiao J; Wang K; Wang T
Chin Med J (Engl); 2008 Sep; 121(18):1821-9. PubMed ID: 19080365
[TBL] [Abstract][Full Text] [Related]
34. Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology.
Sikic BI; Young DM; Mimnaugh EG; Gram TE
Cancer Res; 1978 Mar; 38(3):787-92. PubMed ID: 75060
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice.
Chen XH; Sun RS; Hu JM; Mo ZY; Yang ZF; Jin GY; Guan WD; Zhong NS
Clin Exp Pharmacol Physiol; 2009 Feb; 36(2):146-53. PubMed ID: 18785980
[TBL] [Abstract][Full Text] [Related]
36. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis.
Keane MP; Belperio JA; Moore TA; Moore BB; Arenberg DA; Smith RE; Burdick MD; Kunkel SL; Strieter RM
J Immunol; 1999 May; 162(9):5511-8. PubMed ID: 10228032
[TBL] [Abstract][Full Text] [Related]
37. Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis.
Zhao L; Wang X; Chang Q; Xu J; Huang Y; Guo Q; Zhang S; Wang W; Chen X; Wang J
Eur J Pharmacol; 2010 Feb; 627(1-3):304-12. PubMed ID: 19909737
[TBL] [Abstract][Full Text] [Related]
38. [Effects of cordyceps sinensi on bleomycin-induced pulmonary fibrosis in mice].
Wang SJ; Bai W; Wang CL; Dai Z
Zhongguo Zhong Yao Za Zhi; 2007 Dec; 32(24):2623-7. PubMed ID: 18338602
[TBL] [Abstract][Full Text] [Related]
39. Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis.
Sriram N; Kalayarasan S; Sudhandiran G
Chem Biol Interact; 2009 Jul; 180(2):271-80. PubMed ID: 19497426
[TBL] [Abstract][Full Text] [Related]
40. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis.
Harrison JH; Lazo JS
J Pharmacol Exp Ther; 1987 Dec; 243(3):1185-94. PubMed ID: 2447265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
